MapLight Therapeutics opened lower at $7.46, compared with its previous close of $7.48. In the last trading session, the stock traded between $7.01 and $7.64. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in MapLight Therapeutics is now worth
$ 38.56
Resulting in a loss of
$ 61.44 (61.44%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
60%
Hold
40%
Sell
0%
Markets Today
Today's Change
$-0.41 (-5.45%)
Day High
$7.64
Day Low
$7.01
Day Open
$7.46
Prev Close
$7.48
Volume
2,08,921
1W Return
5.57%
1M Return
-18.02%
3M Return
-41.08%
6M Return
-76.50%
1Y Return
-53.07%
Fundamentals
Market Cap ($ Mn)
374
PE Ratio
-
PB Ratio
1.64
PEG Ratio
-
ROE
-
ROCE
-84.12%
EPS (TTM)
-
Investment Returns
1 Week
5.57%
1 Month
-18.02%
3 Months
-41.08%
6 Months
-76.50%
9 Months
-60.20%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
10Sep
MapLight Therapeutics files prospectus for 13.2m share resale
MapLight Therapeutics filed an SEC prospectus for share resale. The filing covers up to 13,181,055 common shares. Selling stockholders are the parties behind the resale. No operational or financial results were included.
2mo ago
14Aug
MapLight Q2 Results: Net loss widens to $60.2M, cash runway extends to 2028
MapLight Therapeutics reported a Q2 2026 net loss of $60.2 million, widening from $29.8 million in Q2 2025, driven by a 99% YoY rise in R&D expenses to $53.4 million. The company holds $351.3 million in cash, supplemented by a recent $150 million private placement, extending its runway through 2028 to support Phase 3 trials for its lead schizophrenia asset.
3mo ago
11Aug
UBS Downgrades MapLight Therapeutics to Neutral, Cuts Price Target to $13
UBS analyst Ashwani Verma has downgraded MapLight Therapeutics from Buy to Neutral. The price target was reduced from $52 to $13, indicating a bearish outlook on the stock's near-term performance.
MapLight Therapeutics Inc reported positive Phase 2 results for its schizophrenia drug ML-007C-MA, with the 210/3 mg twice-daily dose meeting the primary endpoint. However, the stock fell 65.75% due to the failure of the once-daily dose and concerns over adherence. The company plans FDA meetings to discuss Phase 3 trials.
3mo ago
27Jul
SBS Law probes MapLight Therapeutics over 65% share drop
Schall, Brown & Schwartz LLP investigates MapLight Therapeutics for securities fraud after a 65% stock drop on July 27, 2026. The decline followed mixed Phase 2 trial results where the drug failed to meet statistical significance on its primary endpoint. Affected investors are invited to join the potential class action.
3mo ago
22Jul
UBS raises MapLight Therapeutics price target to $52
UBS analyst Ashwani Verma maintained a Buy rating on MapLight Therapeutics and raised the price target to $52 from $48, signaling a positive outlook on the NASDAQ-listed company's potential.
